
    
      Subjects will be screened for eligibility at the baseline visit for blood tests.

      After screen phase of maximum two weeks the subjects will be randomized to one of two
      treatments groups (1:1): Dunaliella or placebo.

      Each subject will have a final evaluation 4 weeks after the end of study drug treatment.
    
  